Mark This Package Before Anyone Calls It Extra-Label-Eligible

When a veterinarian, veterinary technician, or practice manager pulls a pharmaceutical vial, bottle, or carton from the clinic shelf, an immediate clinical and regulatory question arises: What is the exact legal-marketing status of this physical package? In daily clinical practice, teams frequently need to confirm whether a medication can be administered off-label to a different species, prescribed at a modified dosage interval, dispensed for an unapproved indication, or compounded for a patient with specific formulation constraints.

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), legal marketing is not a vague commercial term. A manufactured animal drug introduced into interstate commerce is legally marketed in the United States only if it is the subject of one of the three routine marketed-package identities on this worksheet:

1. Full Approval: A New Animal Drug Application (NADA) for pioneer brand-name products or an Abbreviated New Animal Drug Application (ANADA) for generic products under section 512 of the FD&C Act (21 U.S.C. § 360b).

2. Conditional Approval: A conditional approval under section 571 of the FD&C Act (21 U.S.C. § 360ccc), granted pending the completion of full effectiveness demonstrations for qualifying minor species or expanded serious/life-threatening conditions.

3. Index Listing: An index listing under section 572 of the FD&C Act (21 U.S.C. § 360ccc-1) on the FDA Index of Legally Marketed Unapproved New Animal Drugs for Minor Species.

If a finished package bears none of those three label identities, it is not a legally marketed animal drug on this worksheet. It may be an unapproved new animal drug. FDA states that unapproved new animal drugs have not been approved, conditionally approved, indexed, or authorized, and that it is illegal to market them. An Emergency Use Authorization under section 564 and an investigational exemption under section 512(j) are separate non-routine paths, not a fourth clinic box. The package might instead be animal food, a USDA biologic, an EPA pesticide, or an approved human drug; those identities are not decided here.

This page is a one-package legal-marketing worksheet. It is for inspecting the container label, discarding NDC, Rx-legend, and facility-slogan lookalikes, mapping the matching federal lookup, and marking whether extra-label use is even available. It does not retell the drug-development pipeline in FDA Veterinary Drug Approval Process Guide, the generic bioequivalence analysis in Generic Veterinary Drugs (ANADA), the clinical mechanics in our Liavium-CA1 Monograph, or the downstream clinical cascade detailed in AMDUCA: Labeled Animal Drug, Extra-Label Use, or Bulk Compounding. Instead, it answers the upstream gatekeeper decision: is this container approved, conditionally approved, indexed, or unapproved?

You Cannot Tell from the Tablet, the NDC, or the Prescription Legend

A common clinical vulnerability in veterinary hospitals is assuming that because a product arrives in professionally finished packaging, features an embossed tablet, or displays formal regulatory lettering, it must be an FDA-approved animal medication. The FDA Center for Veterinary Medicine (CVM) page How can I tell if a drug is legally marketed for animals? (content current as of 12 December 2024) directly warns practitioners: you cannot tell by looking at the tablet or the solution. You have to look at the label.

To establish truthful package identity, clinicians must systematically look past five pervasive label misconceptions:

• Misconception 1: A National Drug Code (NDC) signifies FDA approval. Under 21 CFR Part 207, every commercial drug establishment that manufactures, prepares, propagates, compounds, or processes drugs is legally required to register its establishment and submit a comprehensive list of all marketed drugs to the FDA. The agency assigns an NDC to each listed product for commercial identification and inventory cataloging. The FDA explicitly assigns NDCs to both approved and unapproved drugs. An NDC number confirms that an establishment listed the item; it conveys zero confirmation of safety, efficacy, quality review, or legal marketing status.

• Misconception 2: The veterinary prescription legend proves legal authorization. The federal caution legend—Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian—is mandated by 21 CFR 201.105 on any animal drug that cannot be safely used by a layperson without veterinary diagnosis and supervision. Unapproved prescription animal drugs routinely carry this exact statutory statement. Its presence indicates that the substance requires veterinary oversight, not that the FDA has reviewed or authorized the product.

• Misconception 3: Facility registration slogans convey product clearance. Statements printed on outer packaging such as Registered and listed with the FDA, Manufactured in an FDA-registered facility, Produced in an FDA-inspected plant, or FDA-approved facility are not proof of legal marketing. FDA's identification page tells readers not to take those slogans as approval. FDA registers manufacturing establishments; it does not approve facilities, and registration does not mean the product is a legally marketed animal drug.

• Misconception 4: 'For Veterinary Use Only' confirms approval. Phrases like For Veterinary Use Only or For Animal Use Only represent intended-use demarcations designed to prevent human consumption. They do not constitute a legal marketing authorization or replace an FDA approval statement.

• Misconception 5: Human application numbers validate veterinary use. In the FDA Online Label Repository, drugs display a Marketing Category column. Legitimate human products show New Drug Application (NDA), Abbreviated New Drug Application (ANDA), or Biologics License Application (BLA) classifications. These confirm human approval under section 505 of the FD&C Act, not veterinary approval under section 512. If a clinic dispenses a human NDA/ANDA drug to an animal patient, that administration is an extra-label use of an approved human drug under AMDUCA—it is never an approved animal drug.

Furthermore, brand names cannot be relied upon as stable legal identities. A single pioneer or generic animal drug may be distributed under multiple proprietary distributor trade names through co-packaging or private-label agreements. The front-panel brand name is commercial branding; the application statement and six-digit application or MIF number on the side or back panel provide the sole legal identity.

The Three Statements That Still Count

Because visual inspection and commercial markers are unreliable, veterinary teams must locate one of three exact statutory statements required on the container label or immediate outer packaging. These statements reflect distinct regulatory pathways under the FD&C Act:

To understand how an incoming package is triaged in a hospital setting, review the canonical label inspection workflow illustrated below:

graph TD
    A["Inspect Outer Carton and Primary Container Label"] --> B{"Does label state 'Approved by FDA under NADA #' or 'ANADA #'?"}
    B -- Yes --> C["Full Approval (NADA / ANADA)"]
    C --> C1["Lookup: Animal Drugs @ FDA / Green Book"]
    C1 --> C2["Extra-Label Use Available under AMDUCA 21 CFR 530"]
    B -- No --> D{"Does label state 'Conditionally approved by FDA pending a full demonstration...'?"}
    D -- Yes --> E["Conditional Approval (§ 571)"]
    E --> E1["Lookup: Animal Drugs @ FDA / Green Book"]
    E1 --> E2["Strictly Labeled-Use-Only: Extra-Label Use Prohibited"]
    D -- No --> F{"Does label state 'LEGAL STATUS... THIS PRODUCT IS INDEXED—MIF #'?"}
    F -- Yes --> G["Indexed Minor Species Drug (§ 572)"]
    G --> G1["Lookup: FDA Minor Species Index File"]
    G1 --> G2["Strictly Labeled-Use-Only: Extra-Label Use Prohibited"]
    F -- No --> H["Unapproved New Animal Drug"]
    H --> H1["NDC, Rx legend, or facility slogan do NOT confer legal status"]
    H1 --> H2["Unlawful Interstate Commerce: Do Not Use Off-Label"]

Notice that for extra-label analysis, NADA and ANADA approvals occupy the exact same regulatory tier. In FDA Green Book numbering, pioneer brand approvals receive numbers less than 200-000, while generic copies receive numbers over 200-000. This division reflects the administrative application type (original investigation versus abbreviated bioequivalence), not a distinction in legal standing. Both represent fully approved animal drugs meeting rigorous manufacturing, safety, and effectiveness standards.

Conditional Approval Is Labeled-Use-Only

Conditional approval under section 571 of the FD&C Act (21 U.S.C. § 360ccc) is an essential regulatory mechanism designed to expedite access to therapeutics for underserved veterinary indications. Originally established by the Minor Use and Minor Species Health Act of 2004 (MUMS) for minor species and minor uses in major species, conditional approval was subsequently expanded under the Animal Drug User Fee Act (ADUFA) reauthorization to include certain major species diseases that represent serious or life-threatening conditions or significant animal or human health concerns, where clinical trial endpoints require extended demonstration periods.

However, clinicians frequently confuse conditional approval with full approval. The evidentiary standards governing these two pathways are materially different:

• Safety and Manufacturing: A conditionally approved drug must meet the identical standard of safety as a fully approved NADA. The sponsor must demonstrate target animal safety, environmental safety, human food safety (for food animals), and complete compliance with current Good Manufacturing Practice (cGMP) chemistry, manufacturing, and controls (CMC).

• Effectiveness Standard: Full NADA approval requires substantial evidence of effectiveness established through adequate and well-controlled clinical field investigations. Conditional approval requires the sponsor to demonstrate a reasonable expectation of effectiveness. While preliminary scientific evidence indicates that the drug will achieve its intended therapeutic effect, comprehensive confirmatory data are actively being gathered during commercial distribution.

Because confirmatory effectiveness data remain incomplete, 21 U.S.C. § 360ccc(f)(1) requires the label of a conditionally approved new animal drug, for the conditionally approved use, to bear conditionally approved by FDA pending a full demonstration of effectiveness under application number. That subsection does not use the words extra-label. FDA's Conditional Approval Explained page (content current as of 11 May 2026) states that the FD&C Act does not allow extra-label use of conditionally approved animal drugs, and that every such label must also state: It is a violation of Federal Law to use this product other than as directed in the labeling.

Veterinary professionals should also understand the lifecycle clocks and nomenclature governing conditionally approved products:

1. The 1-Year Plus 4-Renewal Clock: A conditional approval is valid for exactly one year from the date of issuance. The sponsor may apply for annual renewals, up to a maximum of four additional years, allowing a cumulative operational lifecycle of five years. By the 4.5-year milestone, the sponsor must submit all remaining effectiveness data to the FDA. If the sponsor fails to submit sufficient evidence, or if the FDA determines that substantial evidence of effectiveness has not been demonstrated, the conditional approval terminates. The product immediately becomes unapproved and must be withdrawn from the market.

2. These clocks are not a remaining-year countdown for a named SKU: The one-year approval plus up to four annual renewals, and the four-and-a-half-year data deadline, are process facts for the sponsor's marketing right. They are not a remaining-year countdown for Liavium-CA1 or any other named product. If remaining effectiveness information is not submitted by that deadline, or if FDA does not fully approve the drug before five-year termination, FDA says the product is then unapproved and must stop being marketed. Do not invent leftover-stock permission for clinic bottles after termination.

3. The 'CA' Suffix Convention: To provide instant visual identification, conditionally approved medications append a suffix to their proprietary trade name. For example, the designation CA1 indicates the first conditional approval granted for that specific drug formulation. If a second conditional indication were approved, it would be designated CA2. When the sponsor subsequently fulfills all effectiveness requirements and receives full section 512 approval, the 'CA' suffix is permanently dropped from the brand name.

Named products can move from conditional to full approval; that movement is a monograph fact, not this worksheet's identity table. Laverdia (verdinexor) received full FDA approval for canine lymphoma after earlier conditional approval as Laverdia-CA1. KBroVet (potassium bromide) likewise moved from a conditional pathway to full approval for canine idiopathic epilepsy. Liavium-CA1 for Chiari-like malformation in dogs remains a current conditional-approval example. The CA1 suffix is dropped if FDA later fully approves the drug. None of those pages replaces reading the three statements on the package in hand, and a remaining-year clock must not be invented for any named SKU.

Indexed Means Legally Marketed and Still Unapproved

The third statutory marketing mechanism is the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species, authorized under section 572 of the FD&C Act (21 U.S.C. § 360ccc-1) and regulated under 21 CFR Part 516. Understanding indexing requires confronting an apparent contradiction: an indexed drug is legally marketed, yet it is technically unapproved.

Developing a full NADA for specialized companion animal species—such as pet birds, ferrets, pocket pets, zoo animals, or ornamental aquarium species—is frequently economically unviable because the target population is small and potential commercial sales cannot recover the substantial costs of multi-phase clinical safety and effectiveness trials. Congress created the MUMS Index to establish a lawful commercial avenue for these critical minor species medications without requiring standard NADA field trials.

To prevent abuse and protect food safety, federal law imposes strict statutory fences around index eligibility:

• Minor Species Restriction: Indexing is restricted to minor species. Major species—horses, dogs, cats, cattle, pigs, turkeys, and chickens—cannot have an indexed drug. Dogs and cats can still have fully approved or conditionally approved drugs; they simply cannot occupy the Index box.

• Non-Food Animal Limitations: Under 21 CFR § 516.129(c)(7)(i), indexing is permitted for non-food-producing minor species, such as exotic companion mammals, avian pets, and ornamental fish. Under 21 CFR § 516.129(c)(7)(ii), indexing is permitted for early, non-food life stages of food-producing minor species (such as oyster spat or fish hatchlings prior to market entry). Indexing is never permitted for adult food-producing animals consumed by humans.

• The Qualified Expert Panel Mechanism: Indexing relies on a panel of qualified experts outside FDA. The experts review safety in the specific minor species and effectiveness for the intended use. All panel experts must agree that, when used according to the label, benefits outweigh risks to the treated animal. If FDA agrees with the panel, the agency adds the drug to the Index.

On 15 May 2024, the FDA issued a technical final rule (89 FR 42361) amending 21 CFR § 516.155 to align regulatory labeling with modern statutory language enacted under the 2018 User Fee Amendments. The previous label phrase—Not approved by FDA legally marketed as an FDA indexed product—was officially replaced by the current mandatory statement:

Because indexed medications are authorized solely for the discrete minor-species indication confirmed by the expert panel, extra-label use of an indexed animal drug is strictly prohibited under federal law. A clinician cannot prescribe an indexed ferret or reptile medication for an unlisted condition or an unapproved species. Furthermore, indexed products are never listed in Animal Drugs @ FDA or the Green Book; they are cataloged exclusively on the FDA CVM Index of Legally Marketed Unapproved New Animal Drugs for Minor Species.

What This Page Does Not Decide: Extra-Label Use, Rx Versus VFD, Food Versus Drug, and EUA

To maintain operational utility, clinical worksheets must respect strict regulatory boundaries. Confirming that a package possesses full approval, conditional approval, or index listing answers its legal marketing identity. However, that identity must not be conflated with adjacent veterinary regulatory frameworks:

• AMDUCA Extra-Label Clinical Cascade: Confirming that a drug holds full NADA or ANADA approval is merely the prerequisite ticket to enter the AMDUCA framework. Once full approval is verified, clinicians must satisfy every requirement of 21 CFR Part 530 before administering the drug off-label: establishing a valid VCPR, confirming that patient health is threatened or animal suffering will occur without intervention, establishing that no labeled animal drug is clinically available, maintaining comprehensive medical records, extending withdrawal intervals in food animals, and complying with the prohibited extra-label drug list (21 CFR § 530.41). For the clinical execution of this cascade, refer to AMDUCA: Labeled Animal Drug, Extra-Label Use, or Bulk Compounding.

• Prescription (Rx) vs. Over-The-Counter (OTC) vs. Veterinary Feed Directive (VFD): Marketing tiers govern who may dispense or purchase a medication, not whether it is approved. An OTC animal drug (such as certain topical antiseptics or dewormers) still requires a valid NADA or ANADA approval. A VFD drug requires a licensed veterinarian's written order for medicated feed under 21 CFR § 558.6. Determining dispensing access is a separate clinical workflow.

• Food or Supplement vs. Unapproved Drug: When a commercial product claiming to support joint health, calm anxious behavior, or suppress allergy symptoms lacks an application statement, clinicians must determine whether the substance is legally animal food or an unapproved new animal drug. FDA does not recognize a dietary-supplement category for animals. Review that identity in Animal Food vs Unapproved Animal Drug vs Supplement.

• Pharmacy Compounding from Bulk Substances: Under FDA Guidance for Industry (GFI) #256, compounding from bulk drug substances produces an unapproved new animal drug. Enforcement discretion, when FDA's conditions are met, is not approval, conditional approval, or indexing. See Veterinary Compounding Pharmacy Selection (FDA GFI #256).

• Emergency Use Authorization (EUA) under Section 564: An Emergency Use Authorization under section 564 of the FD&C Act (21 U.S.C. § 360bbb-3) is a specialized, temporary crisis mechanism declared during public health or animal health emergencies. An EUA is not a fourth routine clinic box, nor does it constitute full approval without time limitations. An EUA product cannot be used off-label.

One Labeled Fictional Worksheet

Work one stamped-fictional package through present, missing, and unknown fields. It is not a live product, not a purchase recommendation, and not a dose.

Applying our verification framework, the hospital team records the following legal-marketing audit findings:

Through this worksheet, the clinical team arrives at an unambiguous conclusion: On this stamped-fictional packet, the present statement is the conditional-approval pending-effectiveness sentence, so the identity is conditionally approved and extra-label use is not available. The Animal Drugs @ FDA / Green Book lookup and any mixed section-512 approval remain unknown because the packet is not a live SKU. This is not a dose, a remaining-year clock, or a product review.

Sources

This worksheet is grounded in the FD&C Act, 21 CFR, and FDA Center for Veterinary Medicine pages:

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). How can I tell if a drug is legally marketed for animals? Content current as of 12 December 2024. https://www.fda.gov/animal-veterinary/unapproved-animal-drugs/how-can-i-tell-if-drug-legally-marketed-animals

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). FDA Regulation of Animal Drugs. Content current as of 18 October 2024. https://www.fda.gov/animal-veterinary/resources-you/fda-regulation-animal-drugs

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). Conditional Approval Explained: A Resource for Veterinarians. Content current as of 11 May 2026. https://www.fda.gov/animal-veterinary/resources-you/conditional-approval-explained-resource-veterinarians

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). The Ins and Outs of Extra-Label Drug Use in Animals: A Resource for Veterinarians. Content current as of 2 June 2023. https://www.fda.gov/animal-veterinary/resources-you/ins-and-outs-extra-label-drug-use-animals-resource-veterinarians

• U.S. Code of Federal Regulations. Title 21, Part 516, Section 516.155 — Labeling of indexed drugs. Electronic Code of Federal Regulations (eCFR). As amended 15 May 2024. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-E/part-516/section-516.155

• United States Code. Title 21, Section 360ccc — Conditional approval of new animal drugs for minor use and minor species and certain new animal drugs. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/360ccc

• United States Code. Title 21, Section 360ccc-1 — Index of legally marketed unapproved new animal drugs for minor species. Legal Information Institute, Cornell Law School. https://www.law.cornell.edu/uscode/text/21/360ccc-1

• Federal Register. Index of Legally Marketed Unapproved New Animal Drugs for Minor Species (Final Rule). 89 FR 42361, May 15, 2024. https://www.federalregister.gov/documents/2024/05/15/2024-10602/index-of-legally-marketed-unapproved-new-animal-drugs-for-minor-species

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). Unapproved Animal Drugs. Content current as of 7 January 2025. https://www.fda.gov/animal-veterinary/compliance-enforcement/unapproved-animal-drugs

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). How can I use the FDA Online Label Repository to tell if a drug is legally marketed? Content current as of 11 December 2024. https://www.fda.gov/animal-veterinary/unapproved-animal-drugs/how-can-i-use-fda-online-label-repository-tell-if-drug-legally-marketed

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). Approved Animal Drug Products (Green Book). Public registry updated monthly. https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). Animal Drugs @ FDA Database. Online searchable database of approved and conditionally approved animal drugs. https://animaldrugsatfda.fda.gov/

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species. Official registry listing of indexed animal drugs. https://www.fda.gov/animal-veterinary/minor-useminor-species/index-legally-marketed-unapproved-new-animal-drugs-minor-species

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). New Animal Drug Applications (NADA). Statutory overview of section 512 approval requirements. https://www.fda.gov/animal-veterinary/development-approval-process/new-animal-drug-applications

• U.S. Food and Drug Administration, Center for Veterinary Medicine (CVM). New World Screwworm: Information for Veterinarians. Extra-label limits for full approval, conditional approval, indexed products, and EUA, including the mixed-approval exception. Content current as of 11 September 2026. https://www.fda.gov/animal-veterinary/safety-health/new-world-screwworm-information-veterinarians